At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
saracatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC)
In Brief
A Phase 2 clinical trial evaluating saracatinib and laboratory biomarker analysis for Hormone-resistant Prostate Cancer and Recurrent Prostate Cancer. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This phase II trial is studying how well AZD0530 works in treating patients with prostate cancer that did not respond to hormone therapy. AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionOct 2008
TodayJul 2026
First PostedAug 8, 2007
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.9 years ago
Interventions
saracatinibdrug
Given orally
laboratory biomarker analysisother
Correlative studies